Functional genomics: improving cancer prognosis and drug development
Mariani, S.M.
Medgenmed Medscape General Medicine 5(1): 18
2003
ISSN/ISBN: 1531-0132 PMID: 12827079 Document Number: 561339
Document emailed within 1 workday
Related Documents
Buchanan, S.G. 2002: Structural genomics: bridging functional genomics and structure-based drug design Current Opinion in Drug Discovery and Development 5(3): 367-381Rutherford, R.M.; Staedtler, F.; Kehren, J.; Chibout, S-Dine.; Joos, L.; Tamm, M.; Gilmartin, J.J.; Brutsche, M.H. 2004: Functional genomics and prognosis in sarcoidosis--the critical role of antigen presentation Sarcoidosis Vasculitis and Diffuse Lung Diseases: Official Journal of Wasog 21(1): 10-18
Wick, I.; Hardiman, G. 2005: Biochip platforms as functional genomics tools for drug discovery Current Opinion in Drug Discovery and Development 8(3): 347-354
Nasevicius, A.; Ekker, S.C. 2001: The zebrafish as a novel system for functional genomics and therapeutic development applications Current Opinion in Molecular Therapeutics 3(3): 224-228
Encarnación-Guevara, S. 2006: Genomics and functional genomics in microbiology Revista Latinoamericana de Microbiologia 48(2): 131-145
Gilbertsen, V.A. 1970: Improving the prognosis for breast cancer patients Rocky Mountain Medical Journal 67(6): 33-36
Page, R.D.; Argento, A.C.; Nash, D.B.; Skoufalos, A.; Schaefer, E.S. 2017: The Role of Proteomic Testing in Improving Prognosis and Care Planning Quality Measures for Lung Cancer Managed Care 26(9): 37-47
Ma, D.-L. 2004: Approach to the research of human functional genomics in China Zhonghua Yi Xue Za Zhi 84(18): 1497-1498
Kelloff, G.J.; Crowell, J.A.; Boone, C.W.; Steele, V.E.; Lubet, R.A.; Greenwald, P.; Alberts, D.S.; Covey, J.M.; Doody, L.A.; Knapp, G.G. 1994: Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute Journal of Cellular Biochemistry. Supplement 20: 55-62
Cui, G.-H.; Mao, Y.; Huang, L.-Q.; Yuan, Y.; Wang, X.-Y. 2007: Functional genomics studies of Salvia miltiorrhiza III. analyze of metallothionein (MT-2) genes Zhongguo Zhong Yao Za Zhi 32(14): 1393-1395
Bansal, A.T.; Barnes, M.R. 2008: Genomics in drug discovery: the best things come to those who wait Current Opinion in Drug Discovery and Development 11(3): 303-311
Doumbia, S.; Chouong, H.; Traore, S.F.; Dolo, G.; Touré, A.M.; Coulibaly, M. 2007: Establishing an insect disease vector functional genomics training center in Africa African Journal of Medicine and Medical Sciences 36 Suppl: 31-33
Dharia, N.V.; Chatterjee, A.; Winzeler, E.A. 2010: Genomics and systems biology in malaria drug discovery Current Opinion in Investigational Drugs 11(2): 131-138
Agostini, C.; Miorin, M.; Semenzato, G. 2002: Gene expression profile analysis by DNA microarrays: a new approach to assess functional genomics in diseases Sarcoidosis Vasculitis and Diffuse Lung Diseases: Official Journal of Wasog 19(1): 5-9
Descamps, P.; Galais, G.; Body, G.; Lansac, J. 1992: Cancer of the endometrium. Epidemiology, diagnosis, development, prognosis, treatment La Revue du Praticien 42(18): 2365-2371
Holland, K.; Sullivan, M. 2002: Cancer genomics: the chips are on the table New Zealand Medical Journal 115(1163): U204
Zwiebel, J. 2016: The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program Clinical Advances in Hematology and Oncology: H&o 14(3): 157-159
Ripple, G.H.; Wilding, G. 1999: Drug development in prostate cancer Seminars in Oncology 26(2): 217-226
Rajantie, J.; Siimes, M.A. 1985: Improving prognosis in childhood leukemia Duodecim; Laaketieteellinen Aikakauskirja 101(5): 491-497
Schepartz, S.A. 1985: The National Cancer Institute's Drug Development Program Progress in Clinical and Biological Research 197: 73-82